Tuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure on Monday that it halted the development of its investigational weight loss drug ...

The researcher behind the downgrade was top U.S. lender Bank of America, in the person of pundit Bryan Spillane. He changed his view of PepsiCo from buy to neutral, and cut his price target to $155 ...